Unicycive Therapeutics In... (UNCY)
Unicycive Therapeutics Statistics
Share Statistics
Unicycive Therapeutics has 119.7M shares outstanding. The number of shares has increased by 176% in one year.
Shares Outstanding | 119.7M |
Shares Change (YoY) | 176% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | 69.36% |
Shares Floating | 99.26M |
Failed to Deliver (FTD) Shares | 1.37K |
FTD / Avg. Volume | 0.14% |
Short Selling Information
The latest short interest is 1.71M, so 1.65% of the outstanding shares have been sold short.
Short Interest | 1.71M |
Short % of Shares Out | 1.65% |
Short % of Float | 1.77% |
Short Ratio (days to cover) | 1.73 |
Valuation Ratios
The PE ratio is -14.07 and the forward PE ratio is 0.62. Unicycive Therapeutics's PEG ratio is 0.15.
PE Ratio | -14.07 |
Forward PE | 0.62 |
PS Ratio | 0 |
Forward PS | 0.2 |
PB Ratio | 71.59 |
P/FCF Ratio | -18.57 |
PEG Ratio | 0.15 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Unicycive Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.09.
Current Ratio | 1.28 |
Quick Ratio | 1.28 |
Debt / Equity | 0.09 |
Debt / EBITDA | -0.02 |
Debt / FCF | -0.02 |
Interest Coverage | 452.35 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-1.72M |
Employee Count | 22 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -38.46% in the last 52 weeks. The beta is 2.15, so Unicycive Therapeutics's price volatility has been higher than the market average.
Beta | 2.15 |
52-Week Price Change | -38.46% |
50-Day Moving Average | 0.58 |
200-Day Moving Average | 0.52 |
Relative Strength Index (RSI) | 58.93 |
Average Volume (20 Days) | 991.82K |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -32.12M |
Net Income | -37.82M |
EBITDA | -32.12M |
EBIT | -37.9M |
Earnings Per Share (EPS) | -0.06 |
Balance Sheet
The company has 26.14M in cash and 681K in debt, giving a net cash position of 25.46M.
Cash & Cash Equivalents | 26.14M |
Total Debt | 681K |
Net Cash | 25.46M |
Retained Earnings | -101.27M |
Total Assets | 31.67M |
Working Capital | 6.83M |
Cash Flow
In the last 12 months, operating cash flow was -28.57M and capital expenditures -72K, giving a free cash flow of -28.65M.
Operating Cash Flow | -28.57M |
Capital Expenditures | -72K |
Free Cash Flow | -28.65M |
FCF Per Share | -0.04 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
UNCY does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for UNCY is $6, which is 837.5% higher than the current price. The consensus rating is "Buy".
Price Target | $6 |
Price Target Difference | 837.5% |
Analyst Consensus | Buy |
Analyst Count | 3 |
Scores
Altman Z-Score | -7.98 |
Piotroski F-Score | 2 |